Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition

3 Jun 2021

Abstract excerpt

Abstract Purpose: Cross-resistance renders multiple lines of androgen receptor (AR) signaling inhibitors increasingly futile in metastatic castration-resistant prostate cancer (mCRPC). We sought to determine acquired genomic contributors to cross-resistance. Experimental Design: We collected 458 serial plasma cell-free DNA samples at baseline and progression timepoints from 202 patients with mCRPC receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34083234
DOI: 10.1158/1078-0432.ccr-21-1625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionPMID 34083234Read ↗

Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial TherapySemantic proximity Read ↗

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.Semantic proximity Read ↗

Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.Semantic proximity Read ↗

Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read ↗

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.Semantic proximity Read ↗

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway InhibitorsSemantic proximity Read ↗

Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.